Crossmark

Dual pathway inhibition versus antiplatelet therapy for “symptomatic” lower-extremities peripheral artery disease in diabetes mellitus: a systematic review and a meta-analysis of randomized controlled trials for the development of the Italian guidelines for the treatment of diabetic foot syndrome

Crossref DOI link: https://doi.org/10.1007/s00592-025-02562-8

Published Online: 2025-08-02

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Murdolo, Giuseppe https://orcid.org/0000-0001-5654-1760
Gaggia, Francesco

Bianchini, Eleonora

Monami, Matteo

Miranda, Cesare

Monge, Luca

Uccioli, Luigi

Gargiulo, Mauro

Scatena, Alessia

Scevola, Germano

Stabile, Eugenio

Vermigli, Cristiana https://orcid.org/0000-0003-0005-6541
,

Bernetti, Andrea

Bordieri, Corrado

Cappella, Cristina

De Cassai, Alessandro

Falcone, Marco

Gargiulo, Mauro

Lorenzoni, Valentina

Medea, Gerardo

Miranda, Cesare

Monami, Matteo

Monge, Luca

Scatena, Alessia

Scevola, Germano

Stabile, Eugenio

Stefanon, Laura

Tramonta, Rodolfo

Vermigli, Cristiana

Volpe, Antonio

Uccioli, Luigi
License Information

Text and Data Mining valid from 2025-08-02

Version of Record valid from 2025-08-02
More Information

Article History

Received: 13 April 2025

Accepted: 28 June 2025

First Online: 2 August 2025

Declarations

:

: Ma.Ga. is the PI in RI-RivASA trial: “Studio non interventistico per la valutazione degli effetti del trattamento Rivaroxaban e Aspirina sul decorso clinico, di pazienti affetti da arteriopatia ostruttiva clinicamente severa degli arti inferiori sottoposti ad intervento di rivascolarizzazione, in un contesto real world in Italia”. The other Authors do not have any direct relevant conflicts of interest to disclose.

Document is current

Any future updates will be listed below